- Home
- LBTYB vs APGE Comparison
LBTYB vs APGE Comparison
Compare LBTYB & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | APGE |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | APGE |
|---|---|---|
| Price | $16.20 | $82.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | 8.9K | ★ 561.1K |
| Earning Date | 02-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.20 | $34.34 |
| 52 Week High | $29.01 | $95.32 |
Technical Indicators
Market Signals| Indicator | LBTYB | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 48.09 |
| Support Level | $10.25 | $73.06 |
| Resistance Level | $18.00 | $84.56 |
| Average True Range (ATR) | 1.19 | 3.57 |
| MACD | -0.00 | -1.27 |
| Stochastic Oscillator | 59.00 | 16.29 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.